RG7697

Cat. No.: HY-P10271: FAQs
Data Sheet Handling Instructions

Molarity Calculator

RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property.

For research use only. We do not sell to patients.

RG7697 Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

EC₅₀: 3 pM (GIPR), 5 pM (GLP Receptor)

In Vivo

RG7697 (3-30 nmol/kg, s.c., daily for 7 days; or once every two weeks for 30 days) increases insulin secretion and metabolism, decreases glucose excursion, and ameliorates diet induced type 2 diabetes and obesity in C57BL/6 mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Diet induced type 2 diabete and obesity in C57BL/6 mice^[1]
Dosage:	3-30 nmol/kg
Administration:	s.c., daily for 7 days or once every week for 30 days
Result:	Reduced body weight, blood glucose and food intake. Decreased intraperitoneal glucose tolerance, plasma insulin and cholesterol.

Molecular Weight

4473.04

Formula

C₂₁₁H₃₁₆N₄₆O₆₁

Unlabeled CAS

Sequence

Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Tyr-Leu-Asp-Lys-Gln-Ala-Ala-{Aib}-Glu-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-{Lys(C16 acid)}-NH2

Sequence Shortening

Y-{Aib}-EGTFTSDYSIYLDKQAA-{Aib}-EFVNWLLAGGPSSGAPPPS-{Lys(C16 acid)}-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Schmitt C, et al., Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Oct;19(10):1436-1445. [Content Brief]

[2]. Finan B, et al., Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013 Oct 30;5(209):209ra151. [Content Brief]

RG7697 Related Classifications

Peptides

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

RG7697RG 7697RG-7697GLP Receptortype 2 diabetesobesityC57BL/6 miceantihyperglycemicInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks